Literature DB >> 19429845

Fibroblast growth factors in schizophrenia.

Afke F Terwisscha van Scheltinga1, Steven C Bakker, René S Kahn.   

Abstract

A large association study by O'Donovan et al recently suggested that genetic variation in fibroblast growth factor receptor (FGFR) 2 increases the risk for developing schizophrenia. Fibroblast growth factors (FGFs) are part of the family of glial growth factors; they control the growth and patterning of specific brain structures and regulate the maintenance and repair of neuronal tissues. In addition, a direct interaction was recently found between FGFRs and adenosine A(2A) receptors, leading to corticostriatal plasticity and antagonizing the signaling pathway of dopamine D(2) receptors. These findings make FGFs plausible candidate genes for schizophrenia. Here, we review the role of FGFs in schizophrenia and combine evidence from studies on variations in FGF genes, RNA expression, protein levels, and FGF administration, as well as the effects of medication and environmental risk factors for schizophrenia. These data suggest that changes in the FGF system contribute to schizophrenia and possibly to a wider range of psychiatric disorders. The role of FGFs in schizophrenia and related disorders needs to be studied in more detail.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429845      PMCID: PMC2963056          DOI: 10.1093/schbul/sbp033

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  79 in total

Review 1.  Fibroblast growth factors as regulators of central nervous system development and function.

Authors:  Rosanna Dono
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-04       Impact factor: 3.619

2.  Obstetric complications and schizophrenia: historical and meta-analytic review.

Authors:  Mary Cannon; Peter B Jones; Robin M Murray
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

Review 3.  Fibroblast growth factors and their receptors in oligodendrocyte development: implications for demyelination and remyelination.

Authors:  Rashmi Bansal
Journal:  Dev Neurosci       Date:  2002       Impact factor: 2.984

4.  Fibroblast growth factor-18 reduced infarct volumes and behavioral deficits after transient occlusion of the middle cerebral artery in rats.

Authors:  Jeff L Ellsworth; Richard Garcia; Jin Yu; Mark S Kindy
Journal:  Stroke       Date:  2003-05-08       Impact factor: 7.914

Review 5.  Fibroblast growth factors and their receptors in the central nervous system.

Authors:  Bernhard Reuss; Oliver von Bohlen und Halbach
Journal:  Cell Tissue Res       Date:  2003-07-05       Impact factor: 5.249

6.  Disruption of the neuronal PAS3 gene in a family affected with schizophrenia.

Authors:  D Kamnasaran; W J Muir; M A Ferguson-Smith; D W Cox
Journal:  J Med Genet       Date:  2003-05       Impact factor: 6.318

7.  Pretreatment of donor cells with FGF-2 enhances survival of fetal hippocampal CA3 cell transplants in the chronically lesioned young adult hippocampus.

Authors:  Vandana Zaman; Ashok K Shetty
Journal:  Exp Neurol       Date:  2003-09       Impact factor: 5.330

8.  Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus.

Authors:  Fabio Fumagalli; Francesco Bedogni; Maria Elisabetta Maragnoli; Massimo Gennarelli; Jorge Perez; Giorgio Racagni; Marco Andrea Riva
Journal:  J Neurosci Res       Date:  2003-10-01       Impact factor: 4.164

9.  The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response.

Authors:  Emma-Jane Williams; Frank S Walsh; Patrick Doherty
Journal:  J Cell Biol       Date:  2003-02-10       Impact factor: 10.539

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  23 in total

1.  Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis.

Authors:  Stefan Busse; Hans-Gert Bernstein; Mandy Busse; Hendrik Bielau; Ralf Brisch; Christian Mawrin; Susan Müller; Zoltán Sarnyai; Tomasz Gos; Bernhard Bogerts; Johann Steiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-14       Impact factor: 5.270

2.  MicroRNA-382 expression is elevated in the olfactory neuroepithelium of schizophrenia patients.

Authors:  Eyal Mor; Shin-Ichi Kano; Carlo Colantuoni; Akira Sawa; Ruth Navon; Noam Shomron
Journal:  Neurobiol Dis       Date:  2013-03-29       Impact factor: 5.996

3.  Neonatal fibroblast growth factor treatment enhances cocaine sensitization.

Authors:  Sarah M Clinton; Cortney A Turner; Shelly B Flagel; Danielle N Simpson; Stanley J Watson; Huda Akil
Journal:  Pharmacol Biochem Behav       Date:  2012-11       Impact factor: 3.533

4.  Common variants on 8p12 and 1q24.2 confer risk of schizophrenia.

Authors:  Yongyong Shi; Zhiqiang Li; Qi Xu; Ti Wang; Tao Li; Jiawei Shen; Fengyu Zhang; Jianhua Chen; Guoquan Zhou; Weidong Ji; Baojie Li; Yifeng Xu; Dengtang Liu; Peng Wang; Ping Yang; Benxiu Liu; Wensheng Sun; Chunling Wan; Shengying Qin; Guang He; Stacy Steinberg; Sven Cichon; Thomas Werge; Engilbert Sigurdsson; Sarah Tosato; Aarno Palotie; Markus M Nöthen; Marcella Rietschel; Roel A Ophoff; David A Collier; Dan Rujescu; David St Clair; Hreinn Stefansson; Kari Stefansson; Jue Ji; Qingzhong Wang; Wenjin Li; Linqing Zheng; Hairong Zhang; Guoyin Feng; Lin He
Journal:  Nat Genet       Date:  2011-10-30       Impact factor: 38.330

Review 5.  Mental disorders and an acidic glycan-from the perspective of polysialic acid (PSA/polySia) and the synthesizing enzyme, ST8SIA2.

Authors:  Chihiro Sato; Masaya Hane
Journal:  Glycoconj J       Date:  2018-07-30       Impact factor: 2.916

6.  Fibroblast Growth Factor 14 Modulates the Neurogenesis of Granule Neurons in the Adult Dentate Gyrus.

Authors:  Musaad A Alshammari; Tahani K Alshammari; Miroslav N Nenov; Federico Scala; Fernanda Laezza
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

Review 7.  Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research.

Authors:  Akiko Hayashi-Takagi; Marquis P Vawter; Kazuya Iwamoto
Journal:  Biol Psychiatry       Date:  2013-10-18       Impact factor: 13.382

8.  Integrated Post-GWAS Analysis Sheds New Light on the Disease Mechanisms of Schizophrenia.

Authors:  Jhih-Rong Lin; Ying Cai; Quanwei Zhang; Wen Zhang; Rubén Nogales-Cadenas; Zhengdong D Zhang
Journal:  Genetics       Date:  2016-10-17       Impact factor: 4.562

Review 9.  FGF binding proteins (FGFBPs): Modulators of FGF signaling in the developing, adult, and stressed nervous system.

Authors:  Thomas Taetzsch; Vanessa L Brayman; Gregorio Valdez
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-06-12       Impact factor: 5.187

10.  Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.

Authors:  Ilona Klejbor; Aaron Kucinski; Scott R Wersinger; Thomas Corso; Jan H Spodnik; Jerzy Dziewiatkowski; Janusz Moryś; Renae A Hesse; Kenner C Rice; Robert Miletich; Ewa K Stachowiak; Michal K Stachowiak
Journal:  Schizophr Res       Date:  2009-07-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.